Regeneron to seek U.S. OK for COVID-19 cocktail to be used for prevention

ZURICH: Regeneron is pursuing U.S. approval for its COVID-19 monoclonal antibody cocktail as a preventative treatment after it helped cut the risk of symptomatic infections in households where someone else is ill, the U.S. drugmaker said on Monday.

REGEN-COV, a combination of casirivimab and imdevimab, protected household contacts from exposure to SARS-CoV-2, with 72% protection against symptomatic infections in the first week, and 93% after that, according to trial data released by the company. In a separate trial, Regeneron also said the treatment reduced overall risk of progressing to symptomatic COVID-19 by 31%, and by 76% after the third day.